

**Supplementary appendix A. Survey questions**

1. Could you please provide an estimate (%) of how many of your patients with metastatic breast cancer (MBC) are:

HR+ HER2- \_\_\_\_\_

HER2+ \_\_\_\_\_

Triple -ve \_\_\_\_\_

2. Please provide an estimate of the performance status (PS) of the majority of your patients at the time of their metastatic breast cancer (MBC) diagnosis

0 \_\_\_\_\_

1 \_\_\_\_\_

2 \_\_\_\_\_

3 \_\_\_\_\_

3. Please provide the percentage (%) of your patients with metastatic breast cancer (MBC) who also have brain metastases (BM)

\_\_\_\_\_

4. Among your metastatic breast cancer (MBC) patients WITH brain metastases (BM), what percentage (%) of them are:

HR+ HER2- \_\_\_\_\_

HER2+ \_\_\_\_\_

Triple -ve \_\_\_\_\_

5. Please provide an estimate (%) of how many of your patients with metastatic breast cancer (MBC) and brain metastases (BM) have the following:

Upfront BM \_\_\_\_\_

Recurrent BM \_\_\_\_\_

6. Do you use any of the following medications to treat HER2+ metastatic breast cancer (MBC) in your practice? (You can select multiple options)

Trastuzumab Yes/No

Pertuzumab Yes/No

T-DM1 Yes/No

T-DXd Yes/No

Neratinib Yes/No

Lapatinib Yes/No

Capecitabine Yes/No

Tucatinib Yes/No

Other (please specify)

7. What local targeted therapy options do you use for treating HER2+ metastatic breast cancer (MBC) WITH brain metastases? (You can select multiple options)

Whole-Brain Radiotherapy Yes/No

Stereotactic body radiation therapy Yes/No

Surgery Yes/No

Surgery + radiation Yes/No

Other (please specify)

8. For HER2+ metastatic breast cancer (MBC) WITHOUT brain metastases (BM), what is your systemic treatment of choice at the different subsequent treatment lines? (Please write your treatment of choice)

First line \_\_\_\_\_

Second line \_\_\_\_\_

Third line \_\_\_\_\_

Beyond \_\_\_\_\_

9. For HER2+ metastatic breast cancer (MBC) WITH brain metastases (BM), what is your systemic treatment of choice at the different subsequent treatment lines? (Please write your treatment of choice)

First line \_\_\_\_\_

Second line \_\_\_\_\_

Third line \_\_\_\_\_

Beyond \_\_\_\_\_

10. For HER2+ metastatic breast cancer (MBC) WITHOUT brain metastases (BM), which of the following investigations do you regularly/routinely apply in your clinical practice? (You may select more than one option)

Local Examination Yes/No

Local Imaging (Mammogram, Ultrasound) Yes/No

Systemic Imaging: TDM Yes/No

Systemic Imaging: PET Yes/No

Systemic imaging: MRI Yes/No

Echocardiogram Yes/No

MUGA LVEF Yes/No

11. Do you perform regular brain imaging for your asymptomatic HER2+ metastatic breast cancer (MBC) patients WITHOUT brain metastases?

Yes/No

12. If you answered yes to the previous question, which imaging do you use? (you may select more than one option)

CT brain scan \_\_\_\_\_

MRI brain scan \_\_\_\_\_

Other (please specify)

13. For HER2+ metastatic breast cancer (MBC) WITH brain metastases (BM), which of the following investigations do you regularly/routinely apply in your clinical practice? (You may select more than one option)

Local Examination Yes/No

Local Imaging (Mammogram, Ultrasound) Yes/No

Systemic Imaging: TDM Yes/No

Systemic Imaging: PET Yes/No

Systemic imaging: MRI Yes/No

Echocardiogram Yes/No

MUGA LVEF Yes/No

Regular Brain Imaging for Asymptomatic Patients Yes/No

If you answered yes to regular brain imaging for asymptomatic patients, which imaging do you use?

---

14. Is Brain Imaging available in your clinical practice?

\_\_\_\_\_

15. Are Brain MRIs available in your clinical practice?

\_\_\_\_\_

16. Do you experience logistical issues (eg delayed imaging process) in your clinical practice?

\_\_\_\_\_

17. What guidelines do you follow in your clinical practice to treat patients with HER2+ metastatic breast cancer (MBC) with or without brain metastases? (You may choose more than one option)

International guidelines (please specify) \_\_\_\_\_

National guidelines \_\_\_\_\_

Local hospital MDT \_\_\_\_\_

Personal opinion \_\_\_\_\_

Guidelines of choice \_\_\_\_\_

18. Are all drug options for the treatment of metastatic breast cancer (MBC) available to you?

Trastuzumab      Yes/No

Pertuzumab	Yes/No
T-DM1	Yes/No
T-DXd	Yes/No
Neratinib	Yes/No
Lapatinib	Yes/No
Capecitabine	Yes/No
Tucatinib	Yes/NoOther (please specify)